albuterol has been researched along with Adverse Drug Event in 20 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Other measures of asthma control included peak expiratory flow, asthma symptoms, and albuterol use." | 9.13 | Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone. ( Bailey, W; Castro, M; Dransfield, M; Matz, J; Ortega, H; White, M; Yancey, S, 2008) |
| "The purpose of this study was to evaluate how concomitant use of albuterol and vasoactive or inotropes affected ventilator-free days (VFDs) by re-analyzing the data from the Albuterol to Treat Acute Lung Injury (ALTA) trial." | 8.31 | The Potential Synergistic Risk of Albuterol and Vasoactives in Acute Lung Injury Trials. ( Almuntashiri, S; Chase, A; Sikora, A; Zhang, D, 2023) |
| " Other measures of asthma control included peak expiratory flow, asthma symptoms, and albuterol use." | 5.13 | Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone. ( Bailey, W; Castro, M; Dransfield, M; Matz, J; Ortega, H; White, M; Yancey, S, 2008) |
| "The purpose of this study was to evaluate how concomitant use of albuterol and vasoactive or inotropes affected ventilator-free days (VFDs) by re-analyzing the data from the Albuterol to Treat Acute Lung Injury (ALTA) trial." | 4.31 | The Potential Synergistic Risk of Albuterol and Vasoactives in Acute Lung Injury Trials. ( Almuntashiri, S; Chase, A; Sikora, A; Zhang, D, 2023) |
| " Patients with a diagnosis of status asthmaticus who met criteria on continuous albuterol between September 2015 and September 2017 were included." | 3.91 | Implementing a Respiratory Therapist-Driven Continuous Albuterol Weaning Protocol in the Pediatric ICU. ( Beardsley, AL; Hole, AJ; Krupp, NL; Maue, DK; Moser, EA; Rowan, CM; Tori, AJ, 2019) |
| " Food and Drug Administration and featured in the labeling of drugs associated with serious adverse reactions." | 2.46 | FDA boxed warnings: how to prescribe drugs safely. ( O'Connor, NR, 2010) |
| " Using the same stratified data to calculate the sample size required to prove or disprove an association between the use of LABA with mandatory ICS therapy and adverse outcomes, assuming the RD is exactly 0." | 2.45 | Safety of long-acting beta-agonists: are new data really required? ( Sears, MR, 2009) |
| " The time to q2h dosing from initiation of CAN was compared between the baseline and SCAMP cohorts." | 1.46 | A Critical Asthma Standardized Clinical and Management Plan Reduces Duration of Critical Asthma Therapy. ( Agus, MS; Graham, DA; Melendez, E; Wong, J, 2017) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| " Although, the response to bronchoconstriction in dogs and rats was different from humans, the two species presented ventilatory changes that highlight the potential adverse effect of test articles." | 1.35 | Respiratory safety pharmacology: positive control drug responses in Sprague-Dawley rats, Beagle dogs and cynomolgus monkeys. ( Authier, S; Gauvin, D; Legaspi, M; Troncy, E, 2009) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (50.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Almuntashiri, S | 1 |
| Chase, A | 1 |
| Sikora, A | 1 |
| Zhang, D | 1 |
| Marques, L | 3 |
| Vale, N | 3 |
| Maue, DK | 1 |
| Tori, AJ | 1 |
| Beardsley, AL | 1 |
| Krupp, NL | 1 |
| Hole, AJ | 1 |
| Moser, EA | 1 |
| Rowan, CM | 1 |
| Wong, J | 1 |
| Agus, MS | 1 |
| Graham, DA | 1 |
| Melendez, E | 1 |
| Sears, MR | 1 |
| Authier, S | 1 |
| Legaspi, M | 1 |
| Gauvin, D | 1 |
| Troncy, E | 1 |
| O'Connor, NR | 1 |
| Kardos, P | 1 |
| Berdel, D | 1 |
| Buhl, R | 1 |
| Criée, CP | 1 |
| Freihorst, J | 1 |
| Gillissen, A | 1 |
| Karg, O | 1 |
| Pfeifer, M | 1 |
| Magnussen, H | 1 |
| Rabe, KF | 1 |
| Teschler, H | 1 |
| Vogelmeier, C | 1 |
| Welte, T | 1 |
| Wettengel, R | 1 |
| Worth, H | 1 |
| Ryle, PR | 1 |
| Herzyk, DJ | 1 |
| Seymour, SM | 1 |
| Sullivan, EJ | 1 |
| Chowdhury, BA | 1 |
| Meyer, RJ | 1 |
| Davi, RC | 1 |
| Lang, DM | 1 |
| Wang, MT | 1 |
| Skrepnek, GH | 1 |
| Armstrong, E | 1 |
| Sherrill, DL | 1 |
| Harris, RB | 1 |
| Tsai, CL | 1 |
| Malone, DC | 1 |
| Wen, SW | 1 |
| Yang, T | 1 |
| Krewski, D | 1 |
| Yang, Q | 1 |
| Nimrod, C | 1 |
| Garner, P | 1 |
| Fraser, W | 1 |
| Olatunbosun, O | 1 |
| Walker, MC | 1 |
| Bailey, W | 1 |
| Castro, M | 1 |
| Matz, J | 1 |
| White, M | 1 |
| Dransfield, M | 1 |
| Yancey, S | 1 |
| Ortega, H | 1 |
| Salway, JG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Parallel Group, 52-Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Salmeterol 100/50mcg DISKUS® BID or Fluticasone Propionate 10[NCT00102765] | Phase 4 | 479 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for albuterol and Adverse Drug Event
| Article | Year |
|---|---|
Salbutamol in the Management of Asthma: A Review.
Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors | 2022 |
Salbutamol in the Management of Asthma: A Review.
Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors | 2022 |
Salbutamol in the Management of Asthma: A Review.
Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors | 2022 |
Salbutamol in the Management of Asthma: A Review.
Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors | 2022 |
Salbutamol in the Management of Asthma: A Review.
Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors | 2022 |
Salbutamol in the Management of Asthma: A Review.
Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors | 2022 |
Salbutamol in the Management of Asthma: A Review.
Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors | 2022 |
Salbutamol in the Management of Asthma: A Review.
Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors | 2022 |
Salbutamol in the Management of Asthma: A Review.
Topics: Albuterol; Asthma; Bronchi; Drug-Related Side Effects and Adverse Reactions; Humans; Risk Factors | 2022 |
Safety of long-acting beta-agonists: are new data really required?
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Asthma; De | 2009 |
FDA boxed warnings: how to prescribe drugs safely.
Topics: Albuterol; Anti-Bacterial Agents; Bronchodilator Agents; Drug Approval; Drug Labeling; Drug-Related | 2010 |
Justification for routine screening of pharmaceutical products in immune function tests: a review of the recommendations of Putman et al. (2003).
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Buprenorphine; Drug Evaluation, Preclinical; Drug-Rela | 2005 |
The controversy over long-acting beta agonists: examining the evidence.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Asthma; Black or African American; | 2006 |
Drug interference causing misinterpretation of laboratory results. How to solve the problem.
Topics: Albuterol; Biochemistry; Clinical Laboratory Techniques; Computers; Drug-Related Side Effects and Ad | 1978 |
1 trial available for albuterol and Adverse Drug Event
| Article | Year |
|---|---|
Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone.
Topics: Adolescent; Adult; Albuterol; Androstadienes; Asthma; Black or African American; Bronchodilator Agen | 2008 |
13 other studies available for albuterol and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
The Potential Synergistic Risk of Albuterol and Vasoactives in Acute Lung Injury Trials.
Topics: Acute Lung Injury; Administration, Intravenous; Albuterol; Drug-Related Side Effects and Adverse Rea | 2023 |
Implementing a Respiratory Therapist-Driven Continuous Albuterol Weaning Protocol in the Pediatric ICU.
Topics: Albuterol; Bronchodilator Agents; Child; Clinical Protocols; Drug-Related Side Effects and Adverse R | 2019 |
A Critical Asthma Standardized Clinical and Management Plan Reduces Duration of Critical Asthma Therapy.
Topics: Adolescent; Albuterol; Bronchodilator Agents; Child; Child, Preschool; Critical Care; Disease Manage | 2017 |
Respiratory safety pharmacology: positive control drug responses in Sprague-Dawley rats, Beagle dogs and cynomolgus monkeys.
Topics: Albuterol; Animals; Bronchoconstrictor Agents; Bronchodilator Agents; Dogs; Drug Evaluation, Preclin | 2009 |
[Comments of the German Airway League and the German Respiratory Society to the US Food and Drug Administration (FDA)'s announcement from February 18th 2010 on the use of long acting beta-2 agonists in treatment of asthma].
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adult; Adverse Drug Reaction Reportin | 2010 |
Assessing immunotoxicity of pharmaceuticals: the need for enhanced testing.
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Drug-Related Side Effects and Adverse Reactions; Human | 2005 |
Comments on the Salmeterol Multicenter Asthma Research Trial.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Drug-Related Side Effects and Adverse Reactions; Endpoi | 2006 |
Use of salmeterol with and without concurrent use of inhaled corticosteroids and the risk of asthma-related hospitalization among patients with asthma.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Albuterol; Asthma | 2008 |
Patterns of pregnancy exposure to prescription FDA C, D and X drugs in a Canadian population.
Topics: Adult; Albuterol; Contraceptives, Oral; Cross-Sectional Studies; Drug Prescriptions; Drug-Related Si | 2008 |